首页> 外文期刊>Journal of the American Society of Nephrology: JASN >Dialysis, Kidney Transplantation, or Pancreas Transplantation for Patients with Diabetes Mellitus and Renal Failure: A Decision Analysis of Treatment Options
【24h】

Dialysis, Kidney Transplantation, or Pancreas Transplantation for Patients with Diabetes Mellitus and Renal Failure: A Decision Analysis of Treatment Options

机译:糖尿病和肾功能衰竭患者的透析,肾脏移植或胰腺移植:治疗选择的决策分析

获取原文
           

摘要

ABSTRACT. Patients with type 1 diabetes mellitus and end-stage renal disease may remain on dialysis or undergo cadaveric kidney transplantation, living kidney transplantation, sequential pancreas after living kidney transplantation, or simultaneous pancreas-kidney transplantation. It is unclear which of these options is most effective. The objective of this study was to determine the optimal treatment strategy for type 1 diabetic patients with renal failure using a decision analytic Markov model. Input data were obtained from the published medical literature, the United Network for Organ Sharing registry, and patient interviews. The outcome measures were life expectancy (in life-years [LY]) and quality-adjusted life expectancy (in quality-adjusted life-years [QALY]). Living kidney transplantation was associated with 18.30 LY and 10.29 QALY; pancreas after kidney transplantation, 17.21 LY and 10.00 QALY; simultaneous pancreas-kidney transplantation, 15.74 LY and 9.09 QALY; cadaveric kidney transplantation, 11.44 LY and 6.53 QALY; dialysis, 7.82 LY and 4.52 QALY. The results were sensitive to the value of several key variables. Simultaneous pancreas-kidney transplantation had the greatest life expectancy and quality-adjusted life expectancy when living kidney transplantation was excluded from the analysis. These data indicate that living kidney transplantation is associated with the greatest life expectancy and quality-adjusted life expectancy for type 1 diabetic patients with renal failure. Treatment strategies involving pancreas transplantation should be considered for patients with frequent metabolic complications of diabetes and for those patients who favor kidney-pancreas transplantation over kidney transplantation alone. For patients without a living donor, simultaneous pancreas-kidney transplantation is associated with the greatest life expectancy. E-mail: gknoll@ottawahospital.on.ca
机译:抽象。 1型糖尿病和终末期肾脏疾病的患者可继续进行透析或进行尸体肾脏移植,活体肾脏移植,活体肾脏移植后的连续胰腺移植或同时进行胰腺-肾脏移植。尚不清楚这些选项中哪个最有效。这项研究的目的是使用决策分析马尔可夫模型确定1型糖尿病肾衰竭患者的最佳治疗策略。输入数据来自已出版的医学文献,器官共享联合网络注册表和患者访谈。结果指标是预期寿命(以生命年[LY]为单位)和质量调整后的预期寿命(以质量调整后的生命年[QALY]为单位)。活体肾脏移植与18.30 LY和10.29 QALY相关;肾脏移植后胰腺,LY 17.21 LY,QALY 10.00;胰肾联合移植,15.74 LY和9.09 QALY;尸体肾移植,11.44 LY和6.53 QALY;透析,7.82 LY和4.52 QALY。结果对几个关键变量的值敏感。当将活肾移植排除在分析范围之外时,同时进行胰肾肾移植的预期寿命和质量调整后的预期寿命最高。这些数据表明,对于患有肾衰竭的1型糖尿病患者,活体肾脏移植与最大预期寿命和质量调整的预期寿命相关。对于患有频繁的糖尿病代谢并发症的患者,以及那些偏爱肾脏胰腺移植而不是单纯肾脏移植的患者,应考虑涉及胰腺移植的治疗策略。对于没有活体供体的患者,同时进行胰肾肾移植可延长其预期寿命。电子邮件:gknoll@ottawahospital.on.ca

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号